Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

AVACOPAN for Granulomatosis with polyangiitis: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 931 adverse event reports in the FDA FAERS database where AVACOPAN was used for Granulomatosis with polyangiitis.

Most Reported Side Effects for AVACOPAN

Side Effect Reports % Deaths Hosp.
Hospitalisation 520 11.7% 13 507
Off label use 264 5.9% 27 61
Death 254 5.7% 252 30
Fatigue 214 4.8% 2 29
Diarrhoea 211 4.7% 8 38
Nausea 200 4.5% 6 39
Headache 149 3.3% 2 23
Product dose omission issue 145 3.3% 1 30
Pneumonia 143 3.2% 30 98
Covid-19 139 3.1% 18 46
Drug ineffective 111 2.5% 1 29
Therapy interrupted 110 2.5% 2 71
Infection 100 2.2% 31 43
Rash 98 2.2% 2 24
Dizziness 95 2.1% 1 17

Other Indications for AVACOPAN

Product used for unknown indication (966) Anti-neutrophil cytoplasmic antibody positive vasculitis (873) Microscopic polyangiitis (667) Vasculitis (118) Renal disorder (83) Off label use (79) Arteritis (78) Antineutrophil cytoplasmic antibody (41) Antineutrophil cytoplasmic antibody positive (26) Lung disorder (16)

Other Drugs Used for Granulomatosis with polyangiitis

RITUXIMAB (3,222) RITUXIMAB-PVVR (745) METHOTREXATE (456) CYCLOPHOSPHAMIDE (438) PREDNISONE (410) PREDNISOLONE (299) AZATHIOPRINE (265) MYCOPHENOLATE MOFETIL (237) METHYLPREDNISOLONE (210) MYCOPHENOLATE MOFETIL\MYCOPHENOLATE MOFETIL (63)

Related Pages

AVACOPAN Full Profile All Granulomatosis with polyangiitis Drugs AVACOPAN Demographics AVACOPAN Timeline